Endogenous-peptide-dependent alloreactivity: New scientific insights and clinical implications

Tissue Antigens

Volumn 81, Issue 6, 2013, Pages 399-407

  D'Orsogna, Lloyd J ^a,b,c   Nguyen, T H O ^d   Claas, F H J ^e   Witt, C ^a,b   Mifsud, N A ^d  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c MURDOCH UNIVERSITY   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alloreactivity; Haematopoietic stem cell transplantation; HLA; Peptide dependent; Rejection; T cells; Transplantation

Indexed keywords

CD22 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; HLA A2 ANTIGEN; HLA ANTIGEN; HLA B35 ANTIGEN; HLA B44 ANTIGEN; HLA B8 ANTIGEN; HLA C ANTIGEN; HLA DP ANTIGEN; HLA DQ ANTIGEN; IMMUNOSUPPRESSIVE AGENT; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ALLOIMMUNITY; ANTIGEN PRESENTATION; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; NATURAL KILLER CELL; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMANS; ISOANTIGENS; PEPTIDE FRAGMENTS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84877316420     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/tan.12115     Document Type: Review

References (87)

1. Nikolic-Zugic J, Bevan MJ. Role of self-peptides in positively selecting the T-cell repertoire. Nature 1990: 344: 65-7.
2. Sha WC, Nelson CA, Newberry RD et al. Positive selection of transgenic receptor-bearing thymocytes by Kb antigen is altered by Kb mutations that involve peptide binding. Proc Natl Acad Sci USA 1990: 87: 6186-90.
3. Van Kaer L, Ashton-Rickardt PG, Ploegh HL, Tonegawa S. TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4-8+ T cells. Cell 1992: 71: 1205-14.
4. Zijlstra M, Bix M, Simister NE, Loring JM, Raulet DH, Jaenisch R. Beta 2-microglobulin deficient mice lack CD4-8+ cytolytic T cells. Nature 1990: 344: 742-6.
5. Kishimoto H, Sprent J. Negative selection in the thymus includes semimature T cells. J Exp Med 1997: 185: 263-71.
6. Griesemer AD, Sorenson EC, Hardy MA. The role of the thymus in tolerance. Transplantation 2010: 90: 465-74.
7. Zerrahn J, Held W, Raulet DH. The MHC reactivity of the T cell repertoire prior to positive and negative selection. Cell 1997: 88: 627-36.
8. Bankovich AJ, Garcia KC. Not just any T cell receptor will do. Immunity 2003: 18: 7-11.
9. Colf LA, Bankovich AJ, Hanick NA et al. How a single T cell receptor recognizes both self and foreign MHC. Cell 2007: 129: 135-46.
10. Borst J, de Vries E, Spits H, de Vries JE, Boylston AW, Matthews EA. Complexity of T cell receptor recognition sites for defined alloantigens. J Immunol 1987: 139: 1952-9.
11. Mason D. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today 1998: 19: 395-404.
12. Macedo C, Orkis EA, Popescu I et al. Contribution of naive and memory T-cell populations to the human alloimmune response. Am J Transplant 2009: 9: 2057-66.
13. Golshayan D, Wyss JC, Buckland M, Hernandez-Fuentes M, Lechler RI. Differential role of naive and memory CD4 T-cell subsets in primary alloresponses. Am J Transplant 2010: 10: 1749-59.
14. Amir AL, D'Orsogna LJ, Roelen DL et al. Allo-HLA reactivity of virus-specific memory T cells is common. Blood 2010: 115: 3146-57.
15. Heeger PS, Greenspan NS, Kuhlenschmidt S et al. Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol 1999: 163: 2267-75.
16. Lombardi G, Sidhu S, Daly M, Batchelor JR, Makgoba W, Lechler RI. Are primary alloresponses truly primary? Int Immunol 1990: 2: 9-13.
17. Akbar AN, Amlot PL, Timms A, Lombardi G, Lechler R, Janossy G. The development of primed/memory CD8+ lymphocytes in vitro and in rejecting kidneys after transplantation. Clin Exp Immunol 1990: 81: 225-31.
18. Ibrahim S, Dawson DV, Sanfilippo F. Predominant infiltration of rejecting human renal allografts with T cells expressing CD8 and CD45RO. Transplantation 1995: 59: 724-8.
19. Azzawi M, Hasleton PS, Geraghty PJ et al. RANTES chemokine expression is related to acute cardiac cellular rejection and infiltration by CD45RO T-lymphocytes and macrophages. J Heart Lung Transplant 1998: 17: 881-7.
20. Levitsky V, de Campos-Lima PO, Frisan T, Masucci MG. The clonal composition of a peptide-specific oligoclonal CTL repertoire selected in response to persistent EBV infection is stable over time. J Immunol 1998: 161: 594-601.
21. Maecker HT, Maino VC. Analyzing T-cell responses to cytomegalovirus by cytokine flow cytometry. Hum Immunol 2004: 65: 493-9.
22. Benninger-Doring G, Pepperl S, Deml L, Modrow S, Wolf H, Jilg W. Frequency of CD8(+) T lymphocytes specific for lytic and latent antigens of Epstein-Barr virus in healthy virus carriers. Virology 1999: 264: 289-97.
23. D'Orsogna LJ, Amir AL, Zoet YM et al. New tools to monitor the impact of viral infection on the alloreactive T-cell repertoire. Tissue Antigens 2009: 74: 290-7.
24. D'Orsogna LJ, Roelen DL, Doxiadis II, Claas FH. Alloreactivity from human viral specific memory T-cells. Transpl Immunol 2010: 23: 149-55.
25. D'Orsogna LJ, Roelen DL, Doxiadis II, Claas FH. TCR cross-reactivity and allorecognition: new insights into the immunogenetics of allorecognition. Immunogenetics 2012: 64: 77-85.
26. D'Orsogna LJ, van Besouw NM, van der Meer-Prins EM et al. Vaccine-induced allo-HLA-reactive memory T cells in a kidney transplantation candidate. Transplantation 2011: 91: 645-51.
27. Burrows SR, Khanna R, Burrows JM, Moss DJ. An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease. J Exp Med 1994: 179: 1155-61.
28. Gamadia LE, Remmerswaal EB, Surachno S et al. Cross-reactivity of cytomegalovirus-specific CD8+ T cells to allo-major histocompatibility complex class I molecules. Transplantation 2004: 77: 1879-85.
29. Koelle DM, Chen HB, McClurkan CM, Petersdorf EW. Herpes simplex virus type 2-specific CD8 cytotoxic T lymphocyte cross-reactivity against prevalent HLA class I alleles. Blood 2002: 99: 3844-7.
30. Rist M, Smith C, Bell MJ, Burrows SR, Khanna R. Cross-recognition of HLA DR4 alloantigen by virus-specific CD8+ T cells: a new paradigm for self-/nonself-recognition. Blood 2009: 114: 2244-53.
31. Mifsud NA, Nguyen TH, Tait BD, Kotsimbos TC. Quantitative and functional diversity of cross-reactive EBV-specific CD8+ T cells in a longitudinal study cohort of lung transplant recipients. Transplantation 2010: 90: 1439-49.
32. Melenhorst JJ, Leen AM, Bollard CM et al. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood 2010: 116: 4700-2.
33. Gorczynski RM, Rittenberg MB. Analysis of mixed leucocyte culture (MLC) reactive cells after in vitro priming. Changes in avidity of T cell receptors. Cell Immunol 1975: 16: 171-81.
34. Walter S, Herrgen L, Schoor O et al. Cutting edge: predetermined avidity of human CD8 T cells expanded on calibrated MHC/anti-CD28-coated microspheres. J Immunol 2003: 171: 4974-8.
35. Aosai F, Ohlen C, Ljunggren HG et al. Different types of allospecific CTL clones identified by their ability to recognize peptide loading-defective target cells. Eur J Immunol 1991: 21: 2767-74.
36. Felix NJ, Donermeyer DL, Horvath S et al. Alloreactive T cells respond specifically to multiple distinct peptide-MHC complexes. Nat Immunol 2007: 8: 388-97.
37. Crumpacker DB, Alexander J, Cresswell P, Engelhard VH. Role of endogenous peptides in murine allogenic cytotoxic T cell responses assessed using transfectants of the antigen-processing mutant 174xCEM.T2. J Immunol 1992: 148: 3004-11.
38. Alexander-Miller MA, Burke K, Koszinowski UH, Hansen TH, Connolly JM. Alloreactive cytotoxic T lymphocytes generated in the presence of viral-derived peptides show exquisite peptide and MHC specificity. J Immunol 1993: 151: 1-10.
39. Nagy Z. Alloreactivity: an old puzzle revisited. Scand J Immunol 2012: 2012: 463-70.
40. Molina IJ, Huber BT. The expression of a tissue-specific self-peptide is required for allo-recognition. J Immunol 1990: 144: 2082-8.
41. Heath WR, Kane KP, Mescher MF, Sherman LA. Alloreactive T cells discriminate among a diverse set of endogenous peptides. Proc Natl Acad Sci USA 1991: 88: 5101-5.
42. Marrack P, Kappler J. T cells can distinguish between allogeneic major histocompatibility complex products on different cell types. Nature 1988: 332: 840-3.
43. Miltenburg AM, Meijer-Paape ME, Daha MR et al. Donor-specific lysis of human kidney proximal tubular epithelial cells by renal allograft-infiltrating lymphocytes. Transplantation 1989: 48: 296-302.
44. van der Woude FJ, Daha MR, Miltenburg AM et al. Renal allograft-infiltrated lymphocytes and proximal tubular cells: further analysis of donor-specific lysis. Hum Immunol 1990: 28: 186-92.
45. Deckers JG, Daha MR, Van der Kooij SW, Van der Woude FJ. Epithelial- and endothelial-cell specificity of renal graft infiltrating T cells. Clin Transplant 1998: 12: 285-91.
46. Yard BA, Claas FH, Paape ME et al. Recognition of a tissue-specific polymorphism by graft infiltrating T-cell clones isolated from a renal allograft with acute rejection. Nephrol Dial Transplant 1994: 9: 805-10.
47. Archbold JK, Macdonald WA, Miles JJ et al. Alloreactivity between disparate cognate and allogeneic pMHC-I complexes is the result of highly focused, peptide-dependent structural mimicry. J Biol Chem 2006: 281: 34324-32.
48. Macdonald WA, Chen Z, Gras S et al. T cell allorecognition via molecular mimicry. Immunity 2009: 31: 897-908.
49. D'Orsogna LJ, Roelen DL, van der Meer-Prins EM et al. Tissue specificity of cross-reactive allogeneic responses by EBV EBNA3A-specific memory T cells. Transplantation 2011: 91: 494-500.
50. Obst R, Netuschil N, Klopfer K, Stevanovic S, Rammensee HG. The role of peptides in T cell alloreactivity is determined by self-major histocompatibility complex molecules. J Exp Med 2000: 191: 805-12.
51. Morris G, Ni P, Allen P. Alloreactivity is limited by the endogenous peptide repertoire. Proc Natl Acad Sci USA 2011: 108: 3695-700.
52. de Verteuil D, Muratore-Schroeder TL, Granados DP et al. Deletion of immunoproteasome subunits imprints on the transcriptome and has a broad impact on peptides presented by major histocompatibility complex I molecules. Mol Cell Proteomics 2010: 9: 2034-47.
53. Guillaume B, Chapiro J, Stroobant V et al. Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules. Proc Natl Acad Sci USA 2010: 107: 18599-604.
54. Weber DA, Terrell NK, Zhang Y et al. Requirement for peptide in alloreactive CD4+ T cell recognition of class II MHC molecules. J Immunol 1995: 154: 5153-64.
55. Mendiratta SK, Kovalik JP, Hong S, Singh N, Martin WD, Van Kaer L. Peptide dependency of alloreactive CD4+ T cell responses. Int Immunol 1999: 11: 351-60.
56. Yin Y, Mariuzza RA. The multiple mechanisms of T cell receptor cross-reactivity. Immunity 2009: 31: 849-51.
57. Gras S, Kjer-Nielson L, Chen Z, Rossjohn J, McCluskey J. The structural bases of direct T-cell allorecognition: implications for T-cell-mediated transplant rejection. Immunol Cell Biol 2011: 89: 388-95.
58. Gras S, Burrows S, Turner S, Sewell A, McCluskey J, Rossjohn J. A structural voyage toward an understanding of the MHC-I-restricted immune response: lessons learned and much to be learned. Immunol Rev 2012: 250: 61-81.
59. Amir AL, van der Steen DM, Hagedoorn RS et al. Allo-HLA-reactive T cells inducing graft-versus-host disease are single peptide specific. Blood 2011: 118: 6733-42.
60. Reiser JB, Darnault C, Guimezanes A et al. Crystal structure of a T cell receptor bound to an allogeneic MHC molecule. Nat Immunol 2000: 1: 291-7.
61. Shaw BE, Gooley TA, Malkki M et al. The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation. Blood 2007: 110: 4560-6.
62. Crocchiolo R, Zino E, Vago L et al. Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation. Blood 2009: 114: 1437-44.
63. Fleischhauer K, Shaw BE, Gooley T et al. Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. Lancet Oncol 2012: 13: 366-74.
64. Zino E, Frumento G, Marktel S et al. A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation. Blood 2004: 103: 1417-24.
65. Fleischhauer K, Zino E, Mazzi B et al. Peripheral blood stem cell allograft rejection mediated by CD4+ T lymphocytes recognizing a single mismatch at HLA-DP beta 1-0901. Blood 2001: 98: 1122-6.
66. Sizzano F, Zito L, Crivello P et al. Significantly higher frequencies of alloreactive CD4+ T cells responding to nonpermissive than to permissive HLA-DPB1 T-cell epitope disparities. Blood 2010: 116: 1991-2.
67. Vie H, Gaschet J, Milpied N. Permissive, nonpermissive HLA-DPB1 epitope disparities and the specificity of T cells infiltrating the skin during acute graft-versus-host disease. Blood 2011: 117: 5779-81.
68. Rutten CE, van Luxemburg-Heijs SA, Griffioen M et al. HLA-DP as specific target for cellular immunotherapy in HLA class II-expressing B-cell leukemia. Leukemia 2008: 22: 1387-94.
69. Rutten CE, van Luxemburg-Heijs SA, Halkes CJ et al. Patient HLA-DP-specific CD4(+) T cells from HLA-DPB1-mismatched donor lymphocyte infusion can induce graft-versus-leukemia reactivity in the presence or absence of graft-versus-host disease. Biol Blood Marrow Transplant 2013: 19: 40-8.
70. van Bergen J, Thompson A, Haasnoot GW et al. KIR-ligand mismatches are associated with reduced long-term graft survival in HLA-compatible kidney transplantation. Am J Transplant 2011: 11: 1959-64.
71. Fadda L, Borhis G, Ahmed P et al. Peptide antagonism as a mechanism for NK cell activation. Proc Natl Acad Sci USA 2010: 107: 10160-5.
72. Duquesnoy RJ. Antibody-reactive epitope determination with HLA Matchmaker and its clinical applications. Tissue Antigens 2011: 77: 525-34.
73. Mulder A, Eijsink C, Kester MG et al. Impact of peptides on the recognition of HLA class I molecules by human HLA antibodies. J Immunol 2005: 175: 5950-7.
74. Bluestone JA, Kaliyaperumal A, Jameson S, Miller S, Dick R II. Peptide-induced changes in class I heavy chains alter allorecognition. J Immunol 1993: 151: 3943-53.
75. Bluestone JA, Jameson S, Miller S, Dick R II. Peptide-induced conformational changes in class I heavy chains alter major histocompatibility complex recognition. J Exp Med 1992: 176: 1757-61.
76. Catipovic B, Dal Porto J, Mage M, Johansen TE, Schneck JP. Major histocompatibility complex conformational epitopes are peptide specific. J Exp Med 1992: 176: 1611-8.
77. Sherman LA, Chattopadhyay S, Biggs JA, Dick RF II, Bluestone JA. Alloantibodies can discriminate class I major histocompatibility complex molecules associated with various endogenous peptides. Proc Natl Acad Sci USA 1993: 90: 6949-51.
78. Brand A, Doxiadis IN, Roelen DL. On the role of HLA antibodies in hematopoietic stem cell transplantation. Tissue Antigens 2013: 81: 1-11.
79. Weinzierl AO, Rudolf D, Hillen N et al. Features of TAP-independent MHC class I ligands revealed by quantitative mass spectrometry. Eur J Immunol 2008: 38: 1503-10.
80. Wilde S, Sommermeyer D, Frankenberger B et al. Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity. Blood 2009: 114: 2131-9.
81. Mifsud NA, Purcell AW, Chen W, Holdsworth R, Tait BD, McCluskey J. Immunodominance hierarchies and gender bias in direct T(CD8)-cell alloreactivity. Am J Transplant 2008: 8: 121-32.
82. Burrows SR, Khanna R, Moss DJ. Direct alloreactivity by human cytotoxic T lymphocytes can be inhibited by altered peptide ligand antagonism. Blood 1999: 93: 1020-4.
83. Liu Z, Harris PE, Colovai AI, Reed EF, Maffei A, Suciu-Foca N. Suppression of the indirect pathway of T cell reactivity by high doses of allopeptide. Autoimmunity 1995: 21: 173-84.
84. Zoet YM, Eijsink C, Kardol MJ et al. The single antigen expressing lines (SALs) concept: an excellent tool for screening for HLA-specific antibodies. Hum Immunol 2005: 66: 519-25.
85. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003: 9: 543-58.
86. Elmaagacli AH, Steckel NK, Koldehoff M et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood 2011: 118: 1402-12.
87. D'Orsogna LJ, Roelen DL, Doxiadis II, Claas FH. Screening of viral specific T-cell lines for HLA alloreactivity prior to adoptive immunotherapy may prevent GvHD. Transpl Immunol 2011: 24: 141.